Revolution Medicines (RVMD) call put ratio 3.3 calls to 1 put after presented the full results from the Phase 3 RASolute 302 trial evaluating daraxonrasib at ASCO
Go back to Revolution Medicines (RVMD) call put ratio 3.3 calls to 1 put after presented the full results from the Phase 3 RASolute 302 trial evaluating daraxonrasib at ASCO| (NASDAQ: RVMD) | Delayed: 165.81 +2.82 (1.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $162.99 | 52 Week High | $ | |||
| Open | $162.32 | 52 Week Low | $ | |||
| Day High | $166.84 | P/E | N/A | |||
| Day Low | $162.15 | EPS | $ | |||
| Volume | 3,128,201 | |||||
